What is the current valuation of the US tularemia market in 2024?

The overall market valuation was $30.66 Million in 2024. Read More

What is the projected market valuation for the US tularemia market by 2035?

The projected valuation for 2035 is $51.13 Million. Read More

What is the expected CAGR for the US tularemia market during the forecast period 2025 - 2035?

The expected CAGR for the US tularemia market during the forecast period 2025 - 2035 is 4.76%. Read More

Which companies are the key players in the US tularemia market?

Key players in the market include Merck & Co, Sanofi, GlaxoSmithKline, Pfizer, Bayer AG, AbbVie, AstraZeneca, and Novartis. Read More

What are the main segments of the US tularemia market?

The main segments include Diagnosis Method, Treatment Type, End-user, and Infection Type. Read More

What was the market size for serological testing in 2024?

The market size for serological testing was $5.0 Million in 2024. Read More

How much is the market for antibiotic therapy projected to grow by 2035?

The market for antibiotic therapy is projected to grow from $12.2 Million in 2024 to $20.1 Million by 2035. Read More

What is the expected market size for diagnostic laboratories by 2035?

The expected market size for diagnostic laboratories is projected to reach $20.0 Million by 2035. Read More

What are the projected values for oculoglandular tularemia by 2035?

The projected value for oculoglandular tularemia is expected to be $9.0 Million by 2035. Read More

What is the market size for surgical intervention in 2024?

The market size for surgical intervention was $8.96 Million in 2024. Read More

US Tularemia Market

ID: MRFR/Pharma/18519-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Tularemia Market Research Report By Type (ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, others), By Diagnosis (microscopy, immunochemistry, others), By Drugs (streptomycin, gentamicin, doxycycline, ciprofloxacin, others) and By End users (hospitals and clinics, academic and research centers, others) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Diagnosis Method (USD Million)
  1. 4.1.1 Serological Testing
  2. 4.1.2 Molecular Diagnostics
  3. 4.1.3 Culture Testing
  4. 4.1.4 Imaging Techniques
2. 4.2 Life Sciences, BY Treatment Type (USD Million)
  1. 4.2.1 Antibiotic Therapy
  2. 4.2.2 Supportive Care
  3. 4.2.3 Surgical Intervention
3. 4.3 Life Sciences, BY End-user (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Laboratories
  3. 4.3.3 Research Institutions
4. 4.4 Life Sciences, BY Infection Type (USD Million)
  1. 4.4.1 Ulceroglandular Tularemia
  2. 4.4.2 Pneumonic Tularemia
  3. 4.4.3 Oculoglandular Tularemia
  4. 4.4.4 Typhoidal Tularemia
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck & Co (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bayer AG (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AbbVie (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS METHOD
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 US MARKET ANALYSIS BY INFECTION TYPE
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY INFECTION TYPE, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY INFECTION TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
  4. 7.2.4 BY INFECTION TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Diagnosis Method (USD Million, 2025-2035)

Serological Testing
Molecular Diagnostics
Culture Testing
Imaging Techniques

Life Sciences By Treatment Type (USD Million, 2025-2035)

Antibiotic Therapy
Supportive Care
Surgical Intervention

Life Sciences By End-user (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions

Life Sciences By Infection Type (USD Million, 2025-2035)

Ulceroglandular Tularemia
Pneumonic Tularemia
Oculoglandular Tularemia
Typhoidal Tularemia

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”